drugset / Trial / NCT01813773
Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study
Phase 2/3
Completed
20 enrolled
Ophthalmic Consultants of Long Island
Regeneron Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety of intravitreal aflibercept injection in the treatment of proliferative diabetic retinopathy (PDR) by evaluating the incidence and severity of adverse events.
Timeline
- Start
- 2013-03
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |